Combination of CSF <i>N</i> -acetylaspartate and neurofilaments in multiple sclerosis

Abstract

CSF N-acetylaspartate (NAA) levels were not different from patients without neurologic disease in early stages of multiple sclerosis, though decreased as the disease progressed. Combining CSF NAA and neurofilament levels yields information on different phases of axonal pathology.